Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers
Metrics: PDF 2116 views | HTML 2322 views | ?
Teeru Bihani1, Scott A. Ezell1, Brendon Ladd1, Shaun E. Grosskurth1, Anne Marie Mazzola1, Mark Pietras1, Corinne Reimer1, Michael Zinda1, Stephen Fawell1 and Celina M. D’Cruz1
1 AstraZeneca, R&D Boston, Waltham, MA
Celina M. D’Cruz, email:
Keywords: everolimus, resistance, mTOR, MYC, BRD4
Received: October 29, 2014 Accepted: December 10, 2014 Published: December 11, 2014
Acquired resistance to PI3K/mTOR/Akt pathway inhibitors is often associated with compensatory feedback loops involving the activation of oncogenes. Here, we have generated everolimus resistance in ER+ breast cancer cells and in long-term estrogen deprived (LTED) models that mimic progression on anti-estrogens. This allowed us to uncover MYC as a driver of mTOR inhibitor resistance. We demonstrate that both everolimus resistance and acute treatment of everolimus can lead to the upregulation of MYC mRNA, protein expression and, consequently, the enrichment of MYC signatures as revealed by RNA sequencing data. Depletion of MYC resulted in resensitization to everolimus, confirming its functional importance in this setting. Furthermore, ChIP assays demonstrate that MYC upregulation in the everolimus resistant lines is mediated by increased association of the BRD4 transcription factor with the MYC gene. Finally, JQ1, a BRD4 inhibitor combined with everolimus exhibited increased tumor growth inhibition in 3D Matrigel models and an in vivo xenograft model. These data suggest that MYC plays an important role in mediating resistance to everolimus in ER+ and ER+/LTED models. Furthermore, given the regulation ofMYCby BRD4 in this setting, these data have implications for increased therapeutic potential of combining epigenetic agents with mTOR inhibitors to effectively downregulate otherwise difficult to target transcription factors such as MYC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.